Dog model with implanted pump to test boosters for antiretroviral medication

International Journal of Pharmaceutics

Volumn 355, Issue 1-2, 2008, Pages 45-52

  Schueller, Laurent ^a   Baert, Lieven ^a   Lachau Durand, Sophie ^b   Borghys, Herman ^d   Clessens, Ellen ^d   Van Den Mooter, Guy ^e   Van Gyseghem, Elke ^e   Jonckers, Tim H M ^c   Van Remoortere, Pieter ^a   Wigerinck, Piet ^c   Rosier, Jan ^a  

^a Chem Pharm Development   (Belgium)

^b Preclinical Development   (Belgium)

^c Tibotec BVBA   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Booster; Darunavir; Experimental; HIV; Infusion pump; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A5; DARUNAVIR; RITONAVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; INFUSION PUMP; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATA INTERPRETATION, STATISTICAL; DOGS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV PROTEASE INHIBITORS; INFUSION PUMPS, IMPLANTABLE; MALE; RITONAVIR; SULFONAMIDES;

EID: 41549140893     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.025     Document Type: Article

References (20)

1. Baert L., Schueller L., Tardy Y., Macbride D., Van't Klooster G., Borghys H., Clessens E., Van Den Mooter G., Van Gyseghem E., Van Remoortere P., Wigerinck P., and Rosier J. Development of an implantable infusion pump for sustained anti-HIV drug administration 355 (2008) 38-44
2. Bangsberg D.R., Moss A.R., and Deeks S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53 (2004) 696-699
3. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 6 (2004) 123-130
4. ® Model 3000 Series constant flow implantable pump with bolus safety valve. Information by the Manufacturer Codman & Shurtleff of Raynham, Massachusetts, USA. http://www.codman.com/PDFs/3000%20pump.pdf.
5. de Zwart, L.L., Rompelberg, C.J.M., Sips, A.J.A.M., Welink, J., Engelen, J.G.M., 1999. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. RIVM report 623860 010. http://www.rivm.nl/bibliotheek/rapporten/623860010.pdf.
6. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC), October 10, 2006. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://AIDSinfo.nih.gov.
7. Duong M., Buisson M., Peytavin G., Kohli E., Piroth L., Martha B., Grappin M., Chavanet P., and Portier H. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann. Pharmacother. 39 (2005) 603-609
8. Gatti G., Pontali E., Boni S., De Pascalis C.R., Bassetti M., and Bassetti D. The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children. HIV Med. 3 (2002) 125-128
9. Katlama C., Esposito R., Gatell J.M., Goffard J.C., Grinsztejn B., Pozniak A., Rockstroh J., Stoehr A., Vetter N., Yeni P.G., Parys W., Vangeneugden T., and the Power 1 Study Group. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 21 (2007) 395-402
10. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Thippeswamy D., Kincaid J.F., Boross P., Wang Y.F., Tie Y., Volarath P., Gaddis L., Harrison R.W., Weber I.T., Ghosh A.K., and Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
11. Lachau-Durand, S., Raoof, A., Willems, B., Mamidi, S., Meuldermans, W., 2005. The effect of Ritonavir on the pharmacokinetics of TMC114 (Darunavir) in several preclinical species. Pharm. Sci. Fair Exhib., Nice, France, June 12-17: Abstract PO-50.
12. PENTA 5 Study Group. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J. Pediatrics 145 (2004) 403-405
13. POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369 (2007) 1169-1178
14. POWER 2 Study Group. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 21 (2007) F11-F18
15. Rathbun C., Farmer K., Stephens J.R., and Lockhart S.M. Impact of an adherence clinic on the behavioural outcomes and virologic response in treatment of HIV infection, a prospective, randomized, controlled pilot study. Clin. Ther. 27 (2005) 199-209
16. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., and Gallant J.E. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (2003) 1112-1118
17. Tibotec, 2006. PREZISTA™* (darunavir) prescribing information.
18. Torti C., et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin. Infect. Dis. 40 (2005) 1828-1836
19. Wood E., Hogg R., Yip B., Harrigan P.R., O'Shaughnessy M., and Montaner J. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. AIDS 17 (2003) 711-720
20. Wu H., Huang Y., Acosta E.P., Park J.G., Yu S., Rosenkranz S.L., Kuritzkes D.R., Eron J.J., Perelson A.S., and Gerber J.G. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J. Pharmacokinet. Pharmacodyn. 33 (2006) 399-419